P00001606T0076|0 9|Comparison
P00001606T0076|14 33|alkaline phosphatases
P00001606T0076|37 50|5-nucleotidase
P00008171T0000|30 47|hyperbilirubinemia
P00008171T0000|13 19|aspects
P00008997A0472|139 143|slope
P00008997A0472|4 6|CSF
P00008997A0472|34 40|CSF PCO2
P00008997A0472|8 11|HCO3
P00008997A0472|44 47|data
P00008997A0472|98 105|controls
P00008997A0472|24 31|function
P00008997A0472|60 63|rats
P00010943A0733|0 9|Flurazepam
P00010943A0733|96 97|mg
P00010943A0733|81 88|practice
P00010943A0733|69 71|use
P00010943A0733|44 47|drug
P00010943A0733|100 104|night
P00010943A0733|62 65|dose
P00012653T0045|0 3|Beta
P00012653T0045|12 17|agents
P00013683A0210|18 27|CO2 removal
P00013683A0210|68 78|ventilation
P00013683A0210|54 57|VCO2
P00013683A0210|40 52|CO2 production
P00015731A0090|92 107|dichlorphenamide
P00015731A0090|204 211|decrease
P00015731A0090|181 188|increase
P00015731A0090|156 156|p
P00015731A0090|197 200|p CO2
P00015731A0090|11 24|administration
P00015731A0090|64 76|acetazolamide
P00015731A0090|44 62|anhydrase inhibitors
P00015731A0090|78 90|methazolamide
P00015731A0090|214 215|pH
P00015731A0090|142 145|rise
P00015731A0090|191 191|p
P00015731A0090|226 230|blood
P00015731A0090|28 32|mg/kg
P00015731A0090|109 117|sulthiame
P00022143T0000|42 47|rabbit
P00022143T0000|20 30|etoperidone
P00022143T0000|36 38|rat
P00022143T0000|13 17|study
P00023348A0601|10 15|polyps
P00024600A0522|86 98|dosage regimen
P00024600A0522|44 53|advantages
P00024600A0522|11 26|HMG dosage regimen
P00025557A0100|28 28|%
P00025557A0100|7 16|CO2 content
P00025557A0100|32 38|animals
P00025557A0100|59 68|body weight
P00027739T0000|0 28|Serum gamma glutamyltransferase
P00027739T0000|59 64|cattle
P00027739T0000|34 42|diagnosis
P00027739T0000|45 56|liver disease
P00027967A0207|97 105|formation
P00027967A0207|2 9|contrast
P00027967A0207|170 174|onset
P00027967A0207|56 60|onset
P00027967A0207|20 31|HI antibodies
P00027967A0207|80 87|patients
P00027967A0207|177 183|illness
P00027967A0207|148 153|levels
P00027967A0207|161 164|days
P00027967A0207|124 133|antibodies
P00027967A0207|63 69|illness
P00029555A0861|31 42|quantitation
P00029555A0861|18 27|virus assay
P00029555A0861|49 55|methods
P00029555A0861|7 15|exception
P00029555A0861|102 134|shellfish microbiology laboratories
P00029953T0045|0 14|Characteristics
P00029953T0045|17 30|lipase activity
P00030183T0000|0 7|Takayasu
P00030183T0000|18 28|association
P00030183T0000|33 38|HLA-B5
P00030183T0000|10 16|disease
P00030937A0119|0 3|SGPT
P00030937A0119|13 45|alkaline phosphatase concentrations
P00030937A0119|72 79|subjects
P00030937A0119|5 8|SGOT
P00033873T0001|0 26|Gamma glutamyl transpeptidase
P00033873T0001|33 40|activity
P00033873T0001|53 57|fluid
P00033873T0001|28 31|GGTP
P00034935A0545|0 7|Patients
P00034935A0545|96 96|%
P00034935A0545|51 59|incidence
P00034935A0545|23 29|disease
P00034935A0545|77 89|drug treatment
P00034935A0545|62 70|psychoses
P00034935A0545|12 20|Parkinson
P00038408T0000|29 47|alpha-autoreceptors
P00038408T0000|89 91|FLA
P00038408T0000|70 85|alpha-methyldopa
P00038408T0000|9 19|stimulation
P00038408T0000|57 65|treatment
P00039271T0000|49 59|application
P00039271T0000|20 27|diazepam
P00039271T0000|12 17|action
P00039271T0000|65 67|rat
P00041512T0067|0 8|Abstracts
P00048373A0377|0 6|Removal
P00048373A0377|33 38|mucoas
P00048373A0377|78 87|epithelium
P00048373A0377|61 67|absence
P00050628A0202|71 81|proteinuria
P00050628A0202|40 44|serum
P00050628A0202|15 24|gammopathy
P00050628A0202|2 4|IgG
P00050628A0202|93 99|patient
P00050628A0202|48 55|patients
P00052597T0000|0 6|Studies
P00052597T0000|28 33|impact
P00052597T0000|48 61|Professor Dan H.
P00052597T0000|9 23|immunoglobulin E
P00052597T0000|37 43|sojourn
P00054900A0226|50 57|esterase
P00054900A0226|10 23|reaction stains
P00055040A0000|3 14|out-patients
P00055040A0000|243 254|cryoglobulin
P00055040A0000|116 125|fibrinogen
P00055040A0000|92 100|technique
P00055040A0000|104 113|deposition
P00055040A0000|192 195|skin
P00055040A0000|284 288|blood
P00055040A0000|70 87|immunofluorescence
P00055040A0000|19 36|pustulosis palmaris
P00055040A0000|138 156|degradation products
P00055040A0000|229 236|fraction
P00055040A0000|263 278|plasma fibrinogen
P00055040A0000|238 240|HPF
P00055040A0000|158 167|FR-antigen
P00056837A0000|97 105|carcinoma
P00056837A0000|5 21|mediastinoscopies
P00056837A0000|74 84|operability
P00056901A0308|27 46|hydroxy-ethyl-starch
P00056901A0308|57 64|solution
P00056901A0308|15 21|albumin
P00056901A0308|1 7|mixture
P00056901A0308|68 75|dilution
P00056901A0308|23 23|%
P00060529A0695|116 125|percentage
P00060529A0695|215 218|A.B.
P00060529A0695|75 85|0acteriuria
P00060529A0695|27 42|acquisition-rate
P00060529A0695|98 103|figure
P00060529A0695|172 175|year
P00060529A0695|145 162|practice population
P00060529A0695|95 95|%
P00060529A0695|128 132|women
P00060529A0695|12 23|control group
P00061478T0000|48 56|nutrition
P00061478T0000|4 16|complications
P00061478T0000|19 33|catheterisation
P00063680T0000|19 31|galactosaemia
P00063680T0000|8 16|diagnosis
P00064414A1098|0 4|Sings
P00064414A1098|36 49|erythropoiesis
P00066874T0000|89 95|results
P00066874T0000|61 73|contamination
P00066874T0000|100 109|experiment
P00066874T0000|21 47|fluid alpha fetoprotein levels
P00066874T0000|83 87|blood
P00072928T0000|0 13|Serum-ferritin
P00072928T0000|16 24|diagnosis
P00072928T0000|27 42|haemochromatosis
P00073344A0367|41 51|lymphocytes
P00073344A0367|14 35|phytomitogen reactivity
P00073344A0367|68 76|treatment
P00073344A0367|3 10|subjects
P00074758T0000|0 7|Patients
P00074758T0000|16 29|hypothyroidism
P00074758T0000|10 13|risk
P00083846T0000|0 6|Albumin
P00083846T0000|16 24|AMP levels
P00083846T0000|48 52|child
P00083846T0000|37 42|fluids
P00084275T0063|0 6|Preface
P00086313A0000|88 93|groups
P00086313A0000|99 103|basis
P00086313A0000|20 31|Legionnaires
P00086313A0000|33 47|disease bacteria
P00086313A0000|106 113|findings
P00086313A0000|143 157|antibody testing
P00086313A0000|11 17|strains
P00088391A0181|72 78|antigen
P00088391A0181|43 59|coumarin treatment
P00088391A0181|64 69|factor
P00088391A0181|22 29|activity
P00088391A0181|10 19|hand factor
P00089778A0000|298 313|cataract patients
P00089778A0000|3 15|concentration
P00089778A0000|58 68|plasminogen
P00089778A0000|174 178|serum
P00089778A0000|70 82|C3-complement
P00089778A0000|199 203|Fuchs
P00089778A0000|39 56|alpha 1-antitrypsin
P00089778A0000|165 170|humour
P00089778A0000|18 37|alpha 2-macroglobulin
P00089778A0000|228 235|patients
P00089778A0000|259 266|cataract
P00089778A0000|216 224|dystrophy
P00089778A0000|84 112|fibrinogen degradation products
P00089778A0000|114 116|FDP
P00089778A0000|187 194|patients
P00089778A0000|133 140|activity
P00092689A0352|12 19|patients
P00092689A0352|6 6|%
P00092689A0352|35 39|times
P00094639A0313|0 7|Prazosin
P00094639A0313|43 50|patients
P00094639A0313|27 32|volume
P00094639A0313|54 57|dose
P00094639A0313|67 68|mg
P00096241A0087|0 1|T4
P00096241A0087|130 134|weeks
P00096241A0087|116 122|infants
P00096241A0087|145 155|term infants
P00096241A0087|157 157|P
P00096241A0087|5 8|FT4I
P00096241A0087|77 82|values
P00096241A0087|136 138|EGA
P00096241A0087|38 43|groups
P00096241A0087|61 64|days
P00096241A0087|25 31|courses
P00097989A0106|42 49|patients
P00097989A0106|23 36|treatment plans
P00097989A0106|13 20|analysis
P00100540T0000|0 17|Aspirin intolerance
P00100540T0000|44 66|platelet cyclo-oxygenase
P00100540T0000|69 78|inhibition
P00100540T0000|81 87|aspirin
P00100540T0000|28 41|susceptibility
P00100791A0425|87 99|rhesus monkeys
P00100791A0425|135 144|norcocaine
P00100791A0425|5 11|results
P00100791A0425|126 132|effects
P00100791A0425|24 40|cynomolgus monkeys
P00101300A0257|43 44|T3
P00101300A0257|29 35|cancers
P00101300A0257|2 6|cases
P00101300A0257|46 47|N0
P00101300A0257|90 94|years
P00101300A0257|76 80|years
P00101300A0257|49 50|N1
P00101300A0257|63 70|followup
P00101300A0257|37 38|T1
P00101300A0257|99 104|months
P00101300A0257|40 41|T2
P00105401A0635|204 206|FT4
P00105401A0635|52 72|thyroid hormone binding
P00105401A0635|3 8|effect
P00105401A0635|17 19|DPH
P00105401A0635|210 212|FT3
P00105401A0635|122 134|clearance rate
P00105401A0635|137 151|thyroid hormones
P00105401A0635|183 201|premedication levels
P00105401A0635|170 180|maintenance
P00105401A0635|36 47|interference
P00105401A0635|75 77|TBG
P00105401A0635|11 13|CBZ
P00105903A0288|30 40|possibility
P00105903A0288|45 62|polyethylene glycol
P00105903A0288|67 69|PEG
P00105903A0288|10 17|research
P00111174A0351|146 152|stimuli
P00111174A0351|157 163|neurons
P00111174A0351|74 80|neurons
P00111174A0351|45 51|neurons
P00111174A0351|181 187|stimuli
P00111174A0351|107 110|eyes
P00111174A0351|93 99|stimuli
P00111174A0351|115 121|neurons
P00111174A0351|26 35|properties
P00112627A0542|147 151|mg/kg
P00112627A0542|86 98|normeperidine
P00112627A0542|28 32|mg/kg
P00112627A0542|0 12|Pentobarbital
P00112627A0542|132 143|alphaprodine
P00112627A0542|169 173|mg/kg
P00112627A0542|79 83|doses
P00112627A0542|125 129|mg/kg
P00112627A0542|111 121|anileridine
P00112627A0542|157 164|fentanyl
P00112627A0542|104 108|mg/kg
P00112627A0542|49 59|combination
P00113657A0628|0 5|Pb foil
P00113657A0628|39 49|improvement
P00113657A0628|11 15|gcm-2
P00114144A0189|220 231|enzyme defect
P00114144A0189|85 94|hypotheses
P00114144A0189|114 125|similarities
P00114144A0189|130 133|Type
P00114144A0189|28 32|study
P00114144A0189|159 166|Andersen
P00114144A0189|56 69|result emphasis
P00114144A0189|136 157|glycogen storage disease
P00114144A0189|169 175|disease
P00115974A0576|59 62|days
P00115974A0576|3 8|groups
P00115974A0576|35 38|maze
P00115974A0576|65 67|age
P00117748T0000|15 35|clindamycin resistance
P00117748T0000|0 11|Erythromycin
P00117748T0000|68 78|skin lesions
P00117748T0000|38 63|Corynebacterium diphtheriae
P00118044A0000|115 125|EMG activity
P00118044A0000|59 63|peaks
P00118044A0000|14 26|displacements
P00118044A0000|75 81|terms M1
P00118044A0000|29 34|monkey
P00118044A0000|83 84|M2
P00118044A0000|37 41|wrist
P00118044A0000|66 73|activity
P00118044A0000|140 146|muscles
P00118044A0000|89 95|M3 peaks
P00118810T0001|9 15|disease
P00119339A0400|142 153|degeneration
P00119339A0400|170 179|oesophagus
P00119339A0400|94 99|strain
P00119339A0400|158 164|lesions
P00119339A0400|118 128|myocarditis
P00119339A0400|6 11|animal
P00119339A0400|75 87|T. cruzi stocks
P00122718A0500|13 20|MRF units
P00122718A0500|86 93|activity
P00122718A0500|120 127|behavior
P00122718A0500|3 10|majority
P00122718A0500|76 79|case
P00129659T0000|0 10|Variability
P00129659T0000|63 76|sex differences
P00129659T0000|17 20|Down
P00129659T0000|32 41|trisomy-21
P00129659T0000|23 30|syndrome
P00129659T0000|79 81|IQs
P00130573T0054|0 2|VII
P00131739T0001|48 57|Uzbekistan
P00131739T0001|18 24|indices
P00131739T0001|35 45|populations
P00133214T0064|4 11|concepts
P00133214T0064|40 43|USSR
P00133214T0064|27 34|function
P00136175A1137|44 50|density
P00136175A1137|98 105|exercise
P00136175A1137|75 82|exercise
P00136175A1137|140 150|enlargement
P00136175A1137|3 13|maintenance
P00136175A1137|95 95|h
P00136175A1137|67 72|amount
P00136175A1137|111 114|week
P00136175A1137|153 155|ECA
P00137671A0896|100 110|coagulation
P00137671A0896|5 16|observations
P00137671A0896|76 84|indicator
P00137671A0896|50 59|VIII-ratio
P00139624A0318|5 9|hours
P00139624A0318|95 98|rats
P00139624A0318|18 31|administration
P00139624A0318|34 43|colchicine
P00139624A0318|48 70|serum ceruloplasmin level
P00139624A0318|112 115|rats
P00139827A0000|0 16|Radioimmunoassays
P00139827A0000|32 43|progesterone
P00139827A0000|92 98|estriol
P00139827A0000|147 152|plasma
P00139827A0000|127 131|total
P00139827A0000|172 177|course
P00139827A0000|68 70|DHA
P00139827A0000|193 200|delivery
P00139827A0000|45 66|dehydroepiandrosterone
P00139827A0000|137 138|ml
P00139827A0000|19 30|pregnenolone
P00139827A0000|74 90|alpha-hydroxy-DHA
P00139827A0000|103 110|cortisol
P00142718A0156|115 130|chest radiographs
P00142718A0156|40 46|changes
P00142718A0156|68 77|metastases
P00142718A0156|93 102|99mTc-EHDP
P00142718A0156|9 16|patients
P00146327A0147|100 106|trachea
P00146327A0147|13 18|tumors
P00146327A0147|3 10|majority
P00146327A0147|93 98|larynx
P00146327A0147|65 74|incidences
P00146327A0147|110 120|stem bronchi
P00146327A0147|37 44|cavities
P00149899T0001|0 9|Prediction
P00149899T0001|29 39|development
P00149899T0001|15 19|times
P00150066A0100|33 43|coagulation
P00150066A0100|11 20|fibrinogen
P00150066A0100|52 59|thrombin
P00150066A0554|16 27|haemorrhages
P00150066A0554|35 44|prostheses
P00154430A0906|73 85|transcription
P00154430A0906|3 19|Southern technique
P00154430A0906|107 114|fragment
P00154430A0906|92 93|kb
P00154430A0906|35 46|localization
P00154430A0906|52 57|region
P00155973A0387|157 157|%
P00155973A0387|43 48|errors
P00155973A0387|213 229|minute ventilation
P00155973A0387|172 183|gas flow rates
P00155973A0387|116 141|carbon dioxide concentration
P00155973A0387|56 56|%
P00155973A0387|206 210|range
P00155973A0387|194 198|min-1
P00155973A0387|79 84|system
P00155973A0387|26 31|limits
P00155973A0387|153 155|vol
P00155973A0387|237 241|min-1
P00159600A0871|0 1|SV
P00159600A0871|84 86|SHR
P00159600A0871|17 19|SHR
P00159600A0871|149 153|curve
P00159600A0871|56 65|compliance
P00159600A0871|125 129|shift
P00159600A0871|91 99|ventricle
P00163384A0000|28 42|Bubo virginianus
P00163384A0000|3 9|carcass
P00163384A0000|80 86|Ontario
P00163384A0000|103 110|necropsy
P00163384A0000|24 26|owl
P00167544A0067|157 180|surface specimen technique
P00167544A0067|111 128|electron microscopy
P00167544A0067|8 11|ears
P00167544A0067|25 39|microdissection
P00167544A0067|64 70|regions
P00168176A0000|0 6|Patulin
P00168176A0000|83 97|silica gel column
P00168176A0000|117 123|acetate
P00168176A0000|44 55|ethyl acetate
P00168176A0000|136 141|eluant
P00168176A0000|22 39|apple butter samples
P00168176A0000|62 68|extract
P00168431T0000|0 18|Steroid glucuronides
P00168431T0000|29 33|fluid
P00168431T0000|36 39|term
P00172199A0270|101 115|cross striations
P00172199A0270|74 83|appearance
P00172199A0270|3 8|matrix
P00172199A0270|50 59|morphology
P00172199A0270|23 30|clusters
P00173860A0475|0 9|Riboflavin
P00173860A0475|179 183|acids
P00173860A0475|80 96|excretion patterns
P00173860A0475|115 123|magnitude
P00173860A0475|143 153|elimination
P00173860A0475|54 60|animals
P00173860A0475|129 140|disturbances
P00173860A0475|25 34|percentage
P00176742T0000|0 10|Polyglactin
P00176742T0000|14 29|suture absorption
P00176742T0000|50 56|enzymes
P00176742T0000|36 39|role
P00183063A0300|112 119|patients
P00183063A0300|136 143|patients
P00183063A0300|3 11|incidence
P00183063A0300|53 59|cancers
P00183063A0300|78 81|cent
P00183063A0300|35 38|cent
P00183063A0300|63 70|patinets
P00183063A0300|130 133|cent
P00183063A0300|14 26|DNCB reactions
P00183063A0300|95 99|Stage
P00183063A0300|180 185|cancer
P00183063A0300|42 46|Stage
P00183063A0300|103 108|cancer
P00183063A0300|172 176|Stage
P00188387A0975|0 6|Studies
P00188387A0975|56 63|families
P00188387A0975|44 51|children
P00188387A0975|92 103|heart disease
P00188387A0975|9 20|lipoproteins
P00188387A0975|75 76|FH
P00193088A0196|18 25|subjects
P00193088A0196|31 31|g
P00193088A0196|34 43|Metyrapone
P00193088A0196|51 59|responses
P00193587T0000|29 37|phenomena
P00193587T0000|0 12|EEG theta waves
P00193587T0000|49 56|analysis
P00193587T0000|40 45|review
P00196255A0000|0 14|REM dream content
P00196255A0000|176 186|bizarreness
P00196255A0000|99 101|ego
P00196255A0000|61 69|influence
P00196255A0000|27 36|categories
P00196255A0000|79 88|hemisphere
P00196255A0000|154 158|music
P00196255A0000|138 147|hemisphere
P00196255A0000|114 126|verbalization
P00196255A0000|167 174|salience
P00198510T0000|0 10|Innervation
P00198510T0000|44 60|Locusta migratoria
P00198510T0000|23 31|diaphragm
P00198510T0000|37 42|locust
P00199012T0000|31 46|thyroid carcinoma
P00199012T0000|7 18|ACTH syndrome
P00201881A0487|26 32|studies
P00201881A0487|63 68|PI ACTH
P00201881A0487|45 55|correlation
P00201881A0487|9 15|finding
P00201881A0487|72 82|MSH contents
P00205074A0000|55 61|rickets
P00205074A0000|7 22|hypophosphatemia
P00205074A0000|38 41|type
P00209664A0836|28 34|serum LH
P00209664A0836|95 105|correlation
P00209664A0836|66 73|age group
P00209664A0836|132 148|parallel phenomena
P00209664A0836|53 59|bone age
P00209664A0836|10 20|correlation
P00210220X0000|34 38|drugs
P00210220X0000|9 22|neurochemistry
P00211881A0602|126 128|PBB
P00211881A0602|0 6|Efforts
P00211881A0602|29 34|amount
P00211881A0602|118 123|action
P00211881A0602|52 64|kidney lesions
P00211881A0602|112 115|site
P00211881A0602|37 40|time
P00216939T0001|0 5|Effect
P00216939T0001|83 86|rats
P00216939T0001|45 70|acid dehydrogenase reactions
P00216939T0001|107 114|chloride
P00216939T0001|8 15|succimer
P00216939T0001|21 29|intensity
P00216939T0001|76 80|brain
P00219533T0001|15 26|correlations
P00219533T0001|0 11|Distribution
P00219533T0001|88 92|women
P00219533T0001|59 69|populations
P00219533T0001|29 42|serum uric-acid
P00219533T0001|77 79|men
P00219565A0172|14 30|hepatitis B antigen
P00219565A0172|3 11|incidence
P00219565A0172|65 68|cent
P00219565A0172|40 50|transfusion
P00219674A0000|0 13|Technetium-99m
P00219674A0000|146 155|infarction
P00219674A0000|89 96|patients
P00219674A0000|45 55|scintigrams
P00219674A0000|22 34|pyrophosphate
P00219674A0000|114 118|range
P00219674A0000|108 112|weeks
P00221136A0984|39 44|humans
P00221136A0984|8 17|phenomenon
P00221725A0523|43 52|peroxidase
P00221725A0523|15 22|activity
P00221725A0523|85 95|neutrophils
P00221725A0523|3 9|decline
P00221725A0523|133 140|activity
P00221725A0523|110 117|decrease
P00221725A0523|61 72|lipid content
P00221725A0523|25 41|cytochrome oxidase
P00222102A0227|134 141|response
P00222102A0227|0 8|Treatment
P00222102A0227|72 99|alpha-Hydroxycholecalciferol
P00222102A0227|57 67|vitamin-D-3
P00222102A0227|172 184|serum-calcium
P00222102A0227|24 51|pseudohypoparathyroidism type
P00222102A0227|146 151|regard
P00222102A0227|157 169|normalisation
P00222102A0227|12 19|patients
P00222827A0000|59 63|depth
P00222827A0000|0 6|Workers
P00222827A0000|86 95|mechanisms
P00222827A0000|33 44|diisocyanate
P00222827A0000|68 74|attempt
P00222827A0000|46 48|TDI
P00222827A0000|107 121|hyperreactivity
P00222827A0000|12 22|sensitivity
P00224013A0661|26 31|groups
P00224013A0661|117 120|fall
P00224013A0661|54 60|limb VO2
P00224013A0661|260 269|comparison
P00224013A0661|5 7|VO2
P00224013A0661|145 154|resistance
P00224013A0661|422 428|hypoxia
P00224013A0661|167 173|hypoxia
P00224013A0661|236 243|delivery
P00224013A0661|335 359|beta-Vasodilator receptors
P00224013A0661|392 405|vasodilatation
P00224013A0661|89 93|group
P00224013A0661|216 226|utilization
P00224013A0661|294 309|extraction ratios
P00224013A0661|95 104|beta-Block
P00224013A0661|131 134|limb
P00224013A0661|44 50|hypoxia
P00224013A0661|383 386|part
P00224013A0661|280 283|body
P00224013A0661|326 333|pressure
P00224013A0661|254 257|limb
P00225352T0000|21 31|alterations
P00225352T0000|53 61|vitamin D3
P00225352T0000|83 90|rat liver
P00225352T0000|50 51|3H
P00225352T0000|37 46|metabolism
P00227393T0000|0 9|Modulation
P00227393T0000|63 96|cytochrome P-450 monooxygenase system
P00227393T0000|48 60|aminophylline
P00227393T0000|12 45|25-hydroxyvitamin D3-24-hydroxylase
P00227610A1593|54 63|messengers
P00227610A1593|31 37|DBP mRNA
P00227610A1593|66 69|SV40
P00227610A1593|73 86|polyoma viruses
P00227610A1593|11 18|respects
P00231555T0001|0 5|Effect
P00231555T0001|46 61|combination drugs
P00231555T0001|74 77|ACTH
P00231555T0001|81 98|cortisol production
P00232354A0286|0 8|Serum ACTH
P00232354A0286|34 43|metyrapone
P00232354A0286|24 30|insulin
P00232456T0000|84 91|leukemia
P00232456T0000|0 6|Anatomy
P00232456T0000|39 41|MH2
P00232456T0000|95 103|carcinoma
P00232456T0000|18 29|gene products
P00232456T0000|120 124|class
P00232456T0000|105 112|evidence
P00232456T0000|32 35|MC29
P00232456T0000|139 143|genes
P00232456T0000|60 71|tumor viruses
P00232456T0000|12 14|RNA
P00234206T0000|0 7|Bertioga
P00234206T0000|75 82|Sao Paulo
P00234206T0000|84 89|Brazil
P00234206T0000|31 45|Bunyamwera group
P00234206T0000|23 29|Anhembi
P00234206T0000|9 18|Guama group
P00234206T0000|54 64|arboviruses
P00234264A0164|0 34|Gamma glutamyl transpeptidase activity
P00234264A0164|84 91|children
P00234264A0164|121 125|weeks
P00234264A0164|104 114|aminopyrine
P00234264A0164|53 57|times
P00234264A0164|77 81|limit
P00234626T0036|0 2|XXI
P00239014A0000|90 100|blood plasma
P00239014A0000|84 87|acid
P00239014A0000|26 31|method
P00239014A0000|79 82|CPIB
P00239014A0000|38 50|determination
P00239169T0000|60 64|study
P00239169T0000|0 23|Dopamine receptor blockade
P00239169T0000|30 41|neuroleptics
P00240016T0033|0 1|V.
P00240518A0000|18 26|procedure
P00240518A0000|33 45|determination
P00240518A0000|78 82|serum
P00240518A0000|51 75|fungicide 5-fluorocytosine
P00242427T0001|4 8|field
P00242427T0001|34 38|nurse
P00242427T0001|11 16|stress
P00254537T0000|32 39|programs
P00254537T0000|5 13|graduates
P00254537T0000|49 59|state boards
P00254537T0000|25 29|types
P00261981A0434|60 63|rats
P00261981A0434|18 34|serum somatomedin A
P00261981A0434|76 82|litters
P00264240A1843|112 120|T clusters
P00264240A1843|152 170|X. laevis oocyte 5S DNA
P00264240A1843|144 149|region
P00264240A1843|3 11|sequences
P00264240A1843|50 56|5S genes
P00264240A1843|24 39|X. borealis oocyte
P00264240A1843|85 92|residues
P00265964A0562|4 12|mechanism
P00265964A0562|34 46|grain boundary
P00267764A0651|40 56|treatment failures
P00267764A0651|4 9|report
P00267764A0651|30 36|reasons
P00267764A0651|91 100|management
P00267764A0651|73 82|philosophy
P00294502T0001|0 8|Diagnosis
P00294502T0001|31 37|Class II
P00294502T0001|39 46|division
P00294502T0001|12 28|treatment planning
P00300314A0132|16 25|infections
P00300314A0132|227 241|treatment cycles
P00300314A0132|116 124|drug death
P00300314A0132|96 110|hospitalization
P00300314A0132|194 197|days
P00300314A0132|54 74|degrees F. granulocytes
P00300314A0132|149 165|calcium leucovorin
P00300314A0132|203 214|methotrexate
P00300314A0132|173 177|mg/m2
P00300314A0132|27 31|fever
P00300314A0132|136 143|patients
P00300314A0132|89 90|mm
P00303189A0247|14 16|way
P00303189A0247|79 86|efficacy
P00303189A0247|45 58|serum chemistry
P00303189A0247|122 128|process
P00303189A0247|36 42|patient
P00303189A0247|24 28|drugs
P00304240A0369|43 50|presence
P00304240A0369|19 23|tests
P00304240A0369|66 72|disease
P00304310A0000|3 11|end-stage
P00304310A0000|113 116|time
P00304310A0000|76 88|stabilization
P00304310A0000|54 64|retinopathy
P00304310A0000|104 110|periods
P00304310A0000|91 96|vision
P00304310A0000|26 30|phase
P00304806A0760|12 36|serum alpha1AT quantitation
P00304806A0760|73 78|groups
P00304806A0760|45 51|infants
P00304806A0760|136 138|mg%
P00304806A0760|5 9|basis
P00304806A0760|107 120|concentrations
P00313766A0666|83 89|control
P00313766A0666|2 9|patients
P00313766A0666|65 72|function
P00313766A0666|105 105|p
P00313766A0666|80 80|%
P00313766A0666|91 95|range
P00313766A0666|53 62|depression
P00313766A0666|103 103|%
P00316723A0558|0 6|Changes
P00316723A0558|31 38|behavior
P00316723A0558|9 18|body weight
P00321261A0104|191 195|women
P00321261A0104|139 144|phases
P00321261A0104|44 63|prostaglandin F2alpha
P00321261A0104|36 39|PGE2
P00321261A0104|20 34|prostaglandin E2
P00321261A0104|10 17|response
P00321261A0104|159 163|cycle
P00321261A0104|105 110|routes
P00330364A0132|230 241|laboratories
P00330364A0132|1 5|total
P00330364A0132|173 177|cases
P00330364A0132|114 122|abscesses
P00330364A0132|64 71|cultures
P00330364A0132|88 92|batch
P00330364A0132|138 152|BCG-vaccination
P00330364A0132|10 19|BCG strains
P00330364A0132|95 101|strains
P00330364A0132|44 50|strains
P00330364A0132|157 163|strains
P00330364A0132|183 197|BCG-vaccination
P00330364A0132|204 210|strains
P00330364A0132|74 76|BCG
P00330364A0132|125 132|children
P00331128A0000|4 9|levels
P00331128A0000|38 45|patients
P00331128A0000|62 68|failure
P00331128A0000|12 26|serum calcitonin
P00331936T0000|0 8|Detection
P00331936T0000|44 78|immunoperoxidase antiglobulin technic
P00331936T0000|26 35|antibodies
P00336354A0543|13 19|serum GH
P00336354A0543|3 10|response
P00336354A0543|74 85|hypoglycemia
P00336354A0543|22 37|arginine infusion
P00336547A0000|233 241|C57/BL/6J
P00336547A0000|3 15|mortality rate
P00336547A0000|124 127|mice
P00336547A0000|266 272|CBA/LAC
P00336547A0000|67 96|Nocardia brasiliensis infections
P00336547A0000|36 43|features
P00336547A0000|195 198|mice
P00336547A0000|243 257|New Zealand Black
P00336547A0000|277 282|C3H/eB
P00336547A0000|213 224|mouse strains
P00336547A0000|136 148|C3H/eB origins
P00336547A0000|46 63|Nocardia asteroides
P00336547A0000|130 132|ICR
P00336547A0000|259 264|BALB/c
P00337102T0058|0 7|Williams
P00337102T0058|10 15|August
P00339289T0049|0 2|Use
P00339289T0049|29 37|chemistry
P00339289T0049|16 23|isotopes
P00339289T0049|40 47|proteins
P00340692T0033|1 8|Emeritus
P00340692T0033|10 37|John Henri Roosegaarde Bisschop
P00342623A0228|87 96|reactivity
P00342623A0228|49 60|type B antigen
P00342623A0228|20 38|whole-virus vaccines
P00342623A0228|9 16|vaccines
P00350465T0000|34 42|disorders
P00350465T0000|9 17|diagnosis
P00352569A0000|30 44|blood parameters
P00352569A0000|85 89|mg/kg
P00352569A0000|69 73|rates
P00352569A0000|7 18|oxygen supply
P00352569A0000|105 113|endotoxin
P00354315T0000|20 27|patients
P00354315T0000|32 51|ataxia telangiectasia
P00354315T0000|7 17|dysfunction
P00358945A0225|70 74|weeks
P00358945A0225|18 26|treatment
P00358945A0225|10 15|period
P00361059T0000|1 5|study
P00361059T0000|69 88|clobetasol propionate
P00361059T0000|32 53|diflucortolone valerate
P00361059T0000|57 65|% ointment
P00361059T0000|22 29|efficacy
P00361059T0000|93 101|% ointment
P00361340A0529|29 42|osteodystrophy
P00361340A0529|187 205|hyperparathyroidism
P00361340A0529|65 82|vitamin D deficiency
P00361340A0529|213 219|failure
P00361340A0529|92 100|condition
P00361340A0529|157 168|significance
P00361340A0529|9 17|phenomena
P00361340A0529|114 142|1,25-dihydroxycholecalciferol
P00361340A0529|102 111|deficiency
P00369397A0280|5 7|FSH
P00369397A0280|134 141|controls
P00369397A0280|82 84|FSH
P00369397A0280|56 70|GnRH stimulation
P00369397A0280|43 49|addicts
P00369397A0280|74 80|addicts
P00369397A0280|11 18|LH levels
P00369397A0280|88 95|LH values
P00369683T0000|0 9|Adriamycin
P00369683T0000|30 37|schedule
P00369683T0000|73 84|breast cancer
P00369683T0000|49 56|schedule
P00369683T0000|11 20|comparison
P00369683T0000|62 70|treatment
P00377466A0188|30 36|hormone
P00377466A0188|90 99|oestradiol
P00377466A0188|173 179|disease
P00377466A0188|123 134|testosterone
P00377466A0188|38 39|LH
P00377466A0188|9 16|controls
P00377466A0188|69 71|FSH
P00377466A0188|118 118|P
P00377466A0188|143 151|catabolic
P00377466A0188|105 116|progesterone
P00377466A0188|74 82|prolactin
P00377466A0188|136 136|T
P00377466A0188|42 67|follicle stimulating hormone
P00377466A0188|101 102|E2
P00377466A0188|155 166|healing phase
P00377466A0188|84 87|HPRL
P00378492A0475|0 11|Renin studies
P00378492A0475|200 213|artery stenosis
P00378492A0475|98 116|plasma renin activity
P00378492A0475|67 76|recipients
P00378492A0475|37 44|patients
P00378492A0475|122 143|plasma aldosterone level
P00378492A0475|87 95|elevation
P00378492A0475|51 62|control group
P00378735A0000|259 266|carriers
P00378735A0000|82 86|blood
P00378735A0000|171 174|days
P00378735A0000|145 145|g
P00378735A0000|68 72|fever
P00378735A0000|90 102|marrow culture
P00378735A0000|40 47|patients
P00378735A0000|114 124|amoxycillin
P00378735A0000|188 202|chloramphenicol
P00378735A0000|270 281|relapse rates
P00378735A0000|19 23|trial
P00378735A0000|250 256|respect
P00378735A0000|207 212|regard
P00378735A0000|226 244|temperature response
P00378735A0000|128 141|dosage schedule
P00381783T0000|0 29|Bone marrow transplantation-1979
P00383169A0000|119 138|rye-ergot derivatives
P00383169A0000|73 78|agents
P00383169A0000|46 61|dopamine receptor
P00383169A0000|97 107|derivatives
P00383169A0000|80 90|apomorphine
P00383169A0000|6 12|article
P00383169A0000|109 117|piribedil
P00383169A0000|198 207|properties
P00383169A0000|157 161|basis
P00383169A0000|25 31|actions
P00384744T0000|23 34|hypofunction
P00385457A0187|84 90|healing
P00385457A0187|70 78|influence
P00385457A0187|40 44|juice
P00385457A0187|20 25|pepsin
P00385457A0187|8 17|inhibition
P00385457A0187|101 105|ulcer
P00386251A0899|26 34|detection
P00386251A0899|83 102|sulphonamide residues
P00386251A0899|3 19|IDF standard method
P00386251A0899|49 52|milk
P00386251A0899|105 108|milk
P00386251A0899|72 80|detection
P00386251A0899|37 46|penicillin
P00390932T0001|8 15|antigens
P00393598A0198|47 49|ALS
P00393598A0198|3 8|course
P00393598A0198|11 24|endotoxin fever
P00397806T0039|4 16|Algerian cases
P00401521A0138|20 27|patients
P00401521A0138|11 17|percent
P00401521A0138|39 49|ticarcillin
P00401676A0414|71 82|radiotherapy
P00401676A0414|35 42|patients
P00401676A0414|18 24|staging
P00406585T0001|8 17|hematology
P00406585T0001|23 25|age
P00409927A0570|0 7|Neomycin
P00409927A0570|127 135|organisms
P00409927A0570|32 44|staphylococci
P00409927A0570|66 77|streptococci
P00411465A0142|27 33|section
P00411465A0142|51 60|trabeculae
P00411465A0142|67 73|contact
P00411465A0142|42 45|cent
P00411465A0142|86 93|cavities
P00413854A0958|0 6|Changes
P00413854A0958|86 90|blood
P00413854A0958|9 18|tissue PCO2
P00414575T0000|10 19|evaluation
P00414575T0000|27 33|calculi
P00415543A0320|0 10|Recognition
P00415543A0320|133 143|lung disease
P00415543A0320|56 62|quality
P00415543A0320|33 43|radiographs
P00415543A0320|98 102|films
P00415543A0320|107 114|patients
P00415543A0320|91 95|films
P00415543A0320|13 21|emphysema
P00416758T0001|0 8|Isolation
P00416758T0001|44 53|adaptation
P00416758T0001|56 72|laboratory animals
P00416758T0001|31 35|Zaire
P00416758T0001|11 28|T. gambiense strains
P00417166T0000|15 21|profile
P00417166T0000|24 33|clonazepam
P00417166T0000|36 48|rhesus monkeys
P00417301T0001|30 40|brucellosis
P00417301T0001|43 48|humans
P00417301T0001|11 20|mechanisms
P00418341T0000|31 35|parts
P00418341T0000|10 19|adaptation
P00420460A0291|2 9|patients
P00420460A0291|81 86|change
P00420460A0291|150 150|P
P00420460A0291|93 105|blood pressure
P00420460A0291|48 77|log baseline plasma renin activity
P00420460A0291|34 46|drug treatment
P00420460A0291|142 142|r
P00420460A0291|111 112|SQ
P00423649A0259|56 60|claim
P00423649A0259|94 99|regard
P00423649A0259|5 14|techniques
P00423649A0259|78 87|innovation
P00423649A0259|33 38|people
P00423649A0259|46 50|years
P00425547A0000|2 9|patients
P00425547A0000|21 33|osteomyelitis
P00425547A0000|112 116|weeks
P00425547A0000|48 49|os
P00425547A0000|91 100|cephalexin
P00427715A0000|125 134|University
P00427715A0000|1 5|total
P00427715A0000|82 82|B
P00427715A0000|31 37|disease
P00427715A0000|55 63|diaphragm
P00427715A0000|65 70|Stages
P00427715A0000|137 143|Florida
P00427715A0000|99 114|radiation therapy
P00427715A0000|22 28|Hodgkin
P00427715A0000|10 17|patients
P00429151T0000|43 46|unit
P00429151T0000|0 3|Year
P00429151T0000|59 69|Glasgow area
P00429151T0000|24 35|practitioner
P00429893A0000|30 40|round window
P00429893A0000|99 100|mm
P00429893A0000|109 120|scala tympani
P00429893A0000|22 26|array
P00429893A0000|135 140|trauma
P00429893A0000|49 60|implantation
P00429893A0000|126 132|minimum
P00429893A0000|164 174|stimulation
P00429893A0000|79 84|system
P00429949A0000|206 214|prolactin
P00429949A0000|218 228|immunoassay
P00429949A0000|119 126|ampoules
P00429949A0000|17 39|World Health Organization
P00429949A0000|161 193|International Reference Preparation
P00429949A0000|44 58|Expert Committee
P00429949A0000|108 116|prolactin
P00429949A0000|61 85|Biological Standardization
P00429949A0000|195 197|IRP
P00429949A0000|90 100|preparation
P00430889T0001|15 22|fistulas
P00431832T0001|0 15|Plasma ion changes
P00431832T0001|42 61|beta receptor blockers
P00431832T0001|24 28|blood
P00432615A0541|134 145|interference
P00432615A0541|151 164|Sephadex system
P00432615A0541|46 55|literature
P00432615A0541|57 77|heterophile antibodies
P00432615A0541|167 170|RIST
P00432615A0541|10 20|differences
P00432615A0541|91 103|gammaglobulin
P00435187T0000|14 25|flowers bloom
P00437749A0242|42 48|context
P00437749A0242|54 63|psychology
P00437749A0242|7 25|treatment modalities
P00437749A0242|104 107|pain
P00437749A0242|75 84|physiology
P00439618T0001|0 15|Lethal Tachmalcor
P00439618T0001|63 71|poisoning
P00439618T0001|23 36|diethylamino-2
P00439618T0001|74 82|childhood
P00439618T0001|54 61|ajmaline
P00439618T0001|39 51|hydroxypropyl
P00439716T0001|32 48|blood flow velocity
P00439716T0001|20 29|evaluation
P00439716T0001|67 73|fistula
P00445259T0000|0 25|Serum ferritin concentration
P00445259T0000|29 48|bone marrow iron stores
P00445720A0263|28 30|SPG
P00445720A0263|73 74|LA
P00445720A0263|56 57|LV
P00445720A0263|46 54|ventricle
P00445720A0263|91 122|high-fidelity pressure transducers
P00445720A0263|66 71|atrium
P00445720A0263|11 26|pressure gradient
P00450367T0000|89 100|hysterectomy
P00450367T0000|103 107|stage
P00450367T0000|62 67|radium
P00450367T0000|120 128|carcinoma
P00450367T0000|39 50|hysterectomy
P00450367T0000|12 16|trail
P00450367T0000|79 84|radium
P00450367T0000|26 37|hysterectomy
P00450559A0269|13 19|patient
P00450559A0269|94 104|thermometer
P00450559A0269|80 87|accuracy
P00450559A0269|43 51|Clinitemp
P00450559A0269|5 9|basis
P00450559A0269|22 27|report
P00450760T0001|0 15|Cryoglobulinemia
P00450760T0001|18 24|Raynaud
P00450760T0001|27 34|syndrome
P00451192A0248|0 3|Data
P00451192A0248|100 119|LV region-of-interest
P00451192A0248|81 85|curve
P00451192A0248|36 50|computer program
P00453780A0430|15 30|serum IgA response
P00453780A0430|119 122|lung
P00453780A0430|100 105|tissue
P00453780A0430|136 141|source
P00453780A0430|44 60|patient population
P00453780A0430|155 157|IgA
P00454780A0340|0 17|Ultimate strengthes
P00454780A0340|84 84|V
P00454780A0340|60 73|titanium alloys
P00454780A0340|81 82|Ta
P00454780A0340|118 126|corrosion
P00454780A0340|36 51|cast cobalt alloys
P00454780A0340|101 112|fatigue limit
P00456424A0000|88 96|heart rate
P00456424A0000|72 84|blood pressure
P00456424A0000|3 9|effects
P00456424A0000|119 125|rabbits
P00456424A0000|56 68|microgram kg-1
P00456424A0000|45 53|clonidine
P00456424A0000|36 41|i.c.i.
P00456424A0000|154 166|cisterna magna
P00456424A0000|141 148|catheter
P00456424A0000|26 34|injection
P00463973A0000|116 118|age
P00463973A0000|0 13|Platelet number
P00463973A0000|72 76|women
P00463973A0000|59 67|pregnancy
P00463973A0000|17 24|life span
P00463973A0000|120 122|SGA
P00463973A0000|48 56|trimester
P00463973A0000|147 153|infants
P00463973A0000|166 177|birth weights
P00463973A0000|124 130|infants
P00463973A0000|138 142|women
P00464387A1185|58 72|disease activity
P00464387A1185|6 17|measurements
P00464387A1185|25 32|serum IgE
P00464387A1185|51 55|index
P00464387A1185|75 78|ABPA
P00465223A0373|58 64|delta PU
P00465223A0373|93 96|mmHg
P00465223A0373|68 74|delta PM
P00465223A0373|90 91|SD
P00465223A0373|17 34|difference betweent
P00465223A0373|6 13|patients
P00465223A0373|50 55|values
P00465681A0000|72 81|blood serum
P00465681A0000|1 4|rise
P00465681A0000|45 52|increase
P00465681A0000|106 119|oxygen pressure
P00465681A0000|131 134|hour
P00465681A0000|89 92|mice
P00465681A0000|7 29|hemoglobin concentration
P00465681A0000|173 177|state
P00465681A0000|123 125|atm
P00465681A0000|159 161|atm
P00465681A0000|149 153|state
P00465681A0000|63 66|iron
P00465829T0000|0 5|Nernst
P00465829T0000|63 72|potentials
P00465829T0000|8 28|Planck analog equations
P00465829T0000|42 54|state membrane
P00473229T0000|0 6|Effects
P00473229T0000|43 59|trichloroethylene
P00473229T0000|61 79|tetrachloroethylene
P00473229T0000|9 25|methylene chloride
P00473229T0000|95 105|development
P00473229T0000|108 119|chick embryos
P00473229T0000|83 89|toluene
P00473229T0000|27 41|trichloroethane
P00473249T0000|0 5|Effect
P00473249T0000|58 77|electroencephalogram
P00473249T0000|24 37|administration
P00473249T0000|80 86|rabbits
P00473249T0000|40 52|streptolysin O
P00474064A0205|130 130|R
P00474064A0205|115 127|phenoperidine
P00474064A0205|44 53|substances
P00474064A0205|18 36|convlusion threshold
P00474064A0205|6 14|situation
P00474064A0205|77 87|mg.kg-1 I.V.
P00474064A0205|177 180|I.V.
P00474064A0205|148 157|sufentanil
P00474064A0205|66 74|pethidine
P00474064A0205|89 99|piritramide
P00474064A0205|103 110|morphine
P00474064A0205|138 145|fentanyl
P00474064A0205|162 162|R
P00476020T0000|43 48|growth
P00476020T0000|3 14|biochemistry
P00476020T0000|25 29|fluid
P00476572A0139|94 98|cases
P00476572A0139|24 29|lesion
P00476572A0139|127 131|cases
P00476572A0139|113 124|radiodensity
P00477794T0000|0 6|Effects
P00477794T0000|101 106|oralis
P00477794T0000|59 65|neurons
P00477794T0000|41 56|response patterns
P00477794T0000|81 97|nuclei principalis
P00477794T0000|26 35|tractotomy
P00478714T0000|0 7|Efficacy
P00478714T0000|33 55|alcohol treatment program
P00479222A0682|0 9|Resistance
P00479222A0682|176 180|years
P00479222A0682|101 114|immersion times
P00479222A0682|152 159|degrees C
P00479222A0682|137 141|fluid
P00479222A0682|86 95|properties
P00479222A0682|143 146|PECF
P00479222A0682|35 45|environment
P00479222A0682|65 73|retention
P00479246T0000|28 40|osteomyelitis
P00481612A1121|58 66|ventricle
P00481612A1121|102 107|action
P00481612A1121|110 117|fentanyl
P00481612A1121|23 31|receptors
P00483716A0366|41 47|carotid
P00483716A0366|2 5|case
P00483716A0366|97 107|anastomosis
P00483716A0366|57 69|carotid artery
P00484177A0242|97 99|VT.
P00484177A0242|4 13|expression
P00484177A0242|50 59|expiration
P00484177A0242|90 94|range
P00484177A0242|26 43|laminar flow regimen
P00484177A0242|76 82|CT value
P00485615A0935|116 123|syndrome
P00485615A0935|141 150|occurrence
P00485615A0935|68 73|entity
P00485615A0935|221 227|surgery
P00485615A0935|158 169|pancreatitis
P00485615A0935|19 27|existence
P00485615A0935|5 8|data
P00485615A0935|51 56|crisis
P00485615A0935|89 98|importance
P00485615A0935|176 186|performance
P00485615A0935|126 130|order
P00488534A0308|2 9|addition
P00488534A0308|147 152|MR rats
P00488534A0308|66 82|defecation numbers
P00488534A0308|22 48|Treatment X Strain interaction
P00488534A0308|113 118|MR rats
P00490336A0181|43 47|m/sec
P00490336A0181|5 22|conduction velocity
P00490336A0181|49 54|group C
P00493818A0422|3 10|failures
P00493818A0422|95 98|days
P00493818A0422|120 128|insertion
P00493818A0422|109 114|months
P00493818A0422|34 51|patient intolerance
P00493818A0422|68 70|fit
P00494659A0391|15 25|metabolites
P00494659A0391|33 47|3-carboxyphenyl
P00494659A0391|85 95|glucuronide
P00494659A0391|98 107|toloxatone
P00494659A0391|52 80|hydroxymethyl-2-oxazolidinone
P00495097A0663|101 106|tissue
P00495097A0663|63 76|fiber synthesis
P00495097A0663|5 19|characteristics
P00495097A0663|83 88|matrix
P00495097A0663|42 49|activity
P00497494A0112|32 36|PACO2
P00497494A0112|3 13|ventilation
P00499588T0000|0 21|Carbohydrate metabolism
P00499588T0000|60 71|sperm studies
P00499588T0000|28 39|semen profile
P00499588T0000|49 55|insulin
P00499588T0000|41 47|glucose
P00503336A0285|81 99|alkaline phosphatase
P00503336A0285|139 146|findings
P00503336A0285|16 19|CAEC
P00503336A0285|29 30|CC
P00503336A0285|103 115|transaminases
P00503336A0285|162 170|diagnosis
P00503336A0285|73 78|levels
P00503336A0285|61 65|fever
P00503336A0285|45 51|attacks
P00503336A0285|121 125|serum
P00503336A0285|34 37|CIEC
P00506559A0000|32 39|furfural
P00506559A0000|12 29|inhalation toxicity
P00506559A0000|64 71|hamsters
P00506649T0000|0 6|Changes
P00506649T0000|58 63|stress
P00506649T0000|19 40|serum protein components
P00509703A0581|5 15|differences
P00509703A0581|54 62|textbooks
P00510341T0036|1 5|study
P00510341T0036|11 20|E.O.R.T.C.
P00512215A0000|58 58|L
P00512215A0000|60 64|f2-f1
P00512215A0000|119 120|f2
P00512215A0000|145 146|L1
P00512215A0000|110 111|f1
P00512215A0000|136 137|L1
P00512215A0000|10 14|study
P00512215A0000|113 117|f2/f1
P00512215A0000|139 140|L2
P00512215A0000|38 56|difference tone level
P00512215A0000|132 133|f1
P00512215A0000|148 149|L2
P00512215A0000|81 90|parameters
P00512215A0000|104 108|input
P00512215A0000|26 35|dependence
P00513284A0000|146 160|pediatrics field
P00513284A0000|199 200|mg
P00513284A0000|38 41|DOTC
P00513284A0000|168 174|results
P00513284A0000|13 23|preparation
P00513284A0000|191 194|DOTC
P00513284A0000|43 52|Vibramycin
P00513284A0000|76 87|tetracycline
P00513284A0000|246 250|mg/kg
P00513284A0000|136 140|study
P00513284A0000|220 221|ml
P00513284A0000|112 123|drip infusion
P00513284A0000|224 238|glucose solution
P00513284A0000|128 133|series
P00513284A0000|54 59|Pfizer
P00513284A0000|26 36|doxycycline
P00513284A1255|14 17|days
P00513284A1255|67 75|functions
P00513284A1255|54 58|liver
P00513284A1255|79 83|blood
P00513284A1255|23 34|DOTC infusion
P00513284A1255|36 50|laboratory tests
P00516545T0001|30 48|erythrocyte membrane
P00516545T0001|114 131|glomerulonephritis
P00516545T0001|85 92|function
P00516545T0001|50 70|peroxidation processes
P00516545T0001|10 24|characteristics
P00516545T0001|95 102|children
P00517890A0468|71 76|levels
P00517890A0468|29 32|mode
P00517890A0468|117 121|onset
P00517890A0468|35 46|transmission
P00517890A0468|79 102|hepatitis A virus excretion
P00517890A0468|10 14|route
P00517890A0468|124 131|jaundice
P00517890A0468|50 59|hepatitis A
P00519173A0126|29 36|evidence
P00519173A0126|5 12|patients
P00519173A0126|39 50|oesophagitis
P00521732T0000|18 25|oestrone
P00521732T0000|47 54|oestriol
P00521732T0000|57 67|pregnancies
P00521732T0000|81 107|steroid sulphatase deficiency
P00521732T0000|7 15|excretion
P00521732T0000|27 43|oestradiol-17 beta
P00524451A0136|190 192|rat
P00524451A0136|72 82|amphetamine
P00524451A0136|179 184|organs
P00524451A0136|154 167|catecholamines
P00524451A0136|22 38|locomotor activity
P00524451A0136|129 132|time
P00524451A0136|108 120|hexobarbitone
P00524451A0136|63 67|death
P00524451A0136|41 44|mice
P00524451A0136|143 151|depletion
P00524451A0136|90 97|toxicity
P00528144T0000|27 32|uptake
P00528144T0000|44 53|tumor cells
P00528144T0000|5 8|role
P00528144T0000|35 41|gallium
P00528144T0000|11 21|transferrin
P00534613A0000|0 10|Irradiation
P00534613A0000|59 65|ability
P00534613A0000|68 76|aggregate
P00534613A0000|18 31|blood platelets
P00534613A0000|95 102|collagen
P00534613A0000|82 90|challenge
P00534613A0000|36 39|UV-A
P00535520A0239|74 88|cholangiography
P00535520A0239|24 29|method
P00535520A0239|11 20|exceptions
P00540707A0255|215 229|PMK implantation
P00540707A0255|99 103|cases
P00540707A0255|58 70|complications
P00540707A0255|44 50|account
P00540707A0255|257 269|vena cephalica
P00540707A0255|249 251|use
P00540707A0255|91 94|rate
P00540707A0255|24 30|results
P00540707A0255|108 122|tip displacement
P00540707A0255|165 171|Authors
P00540707A0255|204 211|approach
P00540707A0255|190 195|method
P00540707A0255|126 139|pouch haematoma
P00541752A1032|128 129|SD
P00541752A1032|68 73|adults
P00541752A1032|7 20|determinations
P00541752A1032|131 135|ng/ml
P00541752A1032|121 124|mean
P00541752A1032|47 52|plasma
P00541752A1032|87 92|values
P00541752A1032|76 82|October
P00541752A1032|38 44|samples
P00550399A0615|15 20|causes
P00550399A0615|23 27|death
P00550399A0615|50 55|groups
P00553858A0000|15 23|operation
P00553858A0000|215 223|operation
P00553858A0000|45 49|world
P00553858A0000|134 142|technique
P00553858A0000|195 204|principles
P00553858A0000|91 100|literature
P00553858A0000|8 12|Grice
P00553858A0000|111 122|publications
P00553858A0000|162 166|terms
P00553858A0000|63 69|account
P00555492A1034|42 50|blood flow
P00555492A1034|85 94|cimetidine
P00555492A1034|5 11|changes
P00555492A1034|122 125|flow
P00555492A1034|106 114|injection
P00555492A1034|74 82|injection
P00555492A1034|152 164|blood pressure
P00555495T0000|0 4|Study
P00555495T0000|103 111|ovulation
P00555495T0000|88 100|re-appearance
P00555495T0000|137 144|delivery
P00555495T0000|7 22|re-establishment
P00555495T0000|117 124|abortion
P00555495T0000|25 33|ovulation
P00555495T0000|65 73|treatment
P00555495T0000|39 49|termination
P00555583T0000|0 15|Pharmacokinetics
P00555583T0000|18 30|Carbamazepine
P00555583T0000|33 35|man
P00555583T0000|38 43|review
P00557559A0170|151 159|organisms
P00557559A0170|5 13|compounds
P00557559A0170|21 25|alpha
P00557559A0170|53 78|N-methylnitrone 1,4-dioxide
P00557559A0170|98 102|agent
P00564032A0724|14 20|content
P00564032A0724|0 6|Changes
P00564032A0724|54 63|mechanisms
P00564032A0724|70 77|pressure
P00564032A0724|92 95|duct
P00564032A0724|101 105|gland
P00564943A0444|0 5|Calves
P00564943A0444|71 78|SBO-milk
P00564943A0444|58 63|calves
P00564943A0444|67 67|T
P00564943A0444|9 16|MCT-milk
P00564943A0444|38 53|blood cholesterol
P00565136T0000|60 65|SO2Cl2
P00565136T0000|18 21|mice
P00565136T0000|55 58|CH2O
P00565136T0000|70 72|Br2
P00565136T0000|31 40|inhalation
P00565136T0000|7 15|mortality
P00565136T0000|48 52|doses
P00565314A0293|0 9|Guinea pigs
P00565314A0293|37 37|g
P00569989A0239|105 110|dPn/dt
P00569989A0239|60 63|time
P00569989A0239|28 47|flow pneumocardiogram
P00569989A0239|75 102|acceleration pneumocardiogram
P00569989A0239|49 52|PnCG
P00569989A0239|5 23|halothane anesthesia
P00569989A0239|154 169|pneumotachograph
P00569989A0239|132 136|apnea
P00574222T0000|31 41|development
P00574222T0000|16 27|implications
P00574222T0000|7 14|kindling
P00574222T0000|51 60|prostheses
P00574956A0304|115 125|equilibrium
P00574956A0304|17 26|stereotypy
P00574956A0304|195 202|dopamine
P00574956A0304|47 50|case
P00574956A0304|78 81|tone
P00574956A0304|253 265|manifestation
P00574956A0304|226 236|development
P00574956A0304|163 169|systems
P00575231A0422|0 3|None
P00575231A0422|9 23|cystometrograms
P00575231A0422|41 60|detrusor contractions
P00577440A0298|40 43|dose
P00577440A0298|5 12|duodenum
P00577440A0298|19 22|part
P00577440A0298|60 81|3H-alpha-acetyldigoxin
P00578648T0048|34 47|administration
P00578648T0048|10 16|effects
P00580106T0000|0 8|Treatment
P00580106T0000|18 24|disease
P00580106T0000|11 16|Graves
P00580151A0706|183 189|effects
P00580151A0706|117 127|convenience
P00580151A0706|83 92|se-T levels
P00580151A0706|164 167|cost
P00580151A0706|133 139|patient
P00580151A0706|108 112|range
P00580151A0706|61 72|testosterone
P00580151A0706|200 204|doses
P00583004A0445|64 87|1,8-diacetoxy-9-anthrone
P00583004A0445|142 154|inflammations
P00583004A0445|35 60|1,8,9-triacetoxyanthracene
P00583004A0445|116 122|lesions
P00583004A0445|160 163|skin
P00583004A0445|10 33|1,8-dihydroxy-9-anthrone
P00583522T0001|30 37|problems
P00583522T0001|52 63|inflammation
P00587791T0054|0 6|Nursing
P00587791T0054|34 41|diseases
P00587791T0054|9 16|patients
P00589073A0000|173 183|infertility
P00589073A0000|129 133|group
P00589073A0000|15 43|plasma prolactin concentrations
P00589073A0000|86 90|phase
P00589073A0000|47 53|samples
P00589073A0000|111 115|women
P00589073A0000|164 170|history
P00589073A0000|138 145|patients
P00589073A0000|103 109|control
P00590594T0000|7 25|allotransplantation
P00592887T0000|18 33|Patent Blue Violet
P00592887T0000|8 15|reaction
P00592887T0000|40 51|lymphography
P00593119T0001|0 8|Screening
P00593119T0001|42 44|IgE
P00593119T0001|27 39|determination
P00593119T0001|65 72|spectrum
P00593119T0001|11 24|asthma patients
P00593119T0001|90 102|IgE antibodies
P00593119T0001|50 62|comprehension
P00594466T0001|14 21|seizures
P00594466T0001|99 109|stimulation
P00594466T0001|3 11|induction
P00594466T0001|45 56|allylglycine
P00594466T0001|66 76|combination
P00594466T0001|25 34|Papio papio
P00594617A0192|89 91|FDP
P00594617A0192|177 184|monomers
P00594617A0192|110 120|nephropathy
P00594617A0192|275 277|ESR
P00594617A0192|193 216|ethanol-gelification test
P00594617A0192|250 256|disease
P00594617A0192|18 28|correlation
P00594617A0192|47 54|presence
P00594617A0192|99 107|incidence
P00594617A0192|69 87|degradation products
P00594617A0192|186 190|Godal
P00594617A0192|161 168|presence
P00594617A0192|258 262|fever
P00594617A0192|233 237|signs
P00594617A0192|129 141|insufficiency
P00597715A0256|14 16|men
P00597715A0256|0 8|One-third
P00597715A0256|97 106|experience
P00597715A0256|152 160|prognosis
P00597715A0256|79 90|FSH elevation
P00597715A0256|118 121|work
P00597715A0256|21 31|azoospermia
P00597715A0256|39 50|sperm density
P00597715A0256|124 129|others
P00598012A0174|28 32|stage
P00598012A0174|2 21|girls prolactin levels
P00598012A0174|52 59|menarche
P00598012A0174|63 66|boys
P00598012A0174|76 81|change
P00598012A0174|84 98|prolactin levels
P00599601A0260|132 141|physiology
P00599601A0260|64 75|pinealectomy
P00599601A0260|166 168|rat
P00599601A0260|104 114|alterations
P00599601A0260|37 46|procedures
P00600943T0001|13 31|lymphomononucleosis
P00600943T0001|1 5|cases
P00601401A0181|57 62|oxygen
P00601401A0181|96 119|delta log Po2/delta pH ratio
P00601401A0181|70 79|Bohr effect
P00601401A0181|6 23|hemoglobin solution
P00601401A0181|46 53|affinity
P00602622A0362|116 123|activity
P00602622A0362|68 68|p
P00602622A0362|82 90|reduction
P00602622A0362|44 48|Roter
P00602622A0362|36 42|Vikalin
P00602622A0362|9 20|ulcer therapy
P00602622A0362|25 32|atropine
P00602702A0309|84 91|function
P00602702A0309|148 155|diarrhea
P00602702A0309|55 59|serum
P00602702A0309|5 11|patient
P00602702A0309|108 127|estriol concentration
P00602702A0309|33 52|estriol concentration
P00602702A0309|22 29|diarrhea
P00603783A0647|0 10|Serum levels
P00603783A0647|68 85|observers IgA levels
P00603783A0647|13 15|IgG
P00603783A0647|53 60|findings
P00603783A0647|19 21|IgM
P00606849T0000|56 62|rabbits
P00606849T0000|20 31|heart disease
P00606849T0000|41 53|thromboxane A2
P00614915T0001|0 9|Vitrectomy
P00614915T0001|18 29|traumatology
P00616575A0000|86 99|decimeter waves
P00616575A0000|117 129|investigation
P00616575A0000|54 59|action
P00616575A0000|106 107|DW
P00616575A0000|79 83|field
P00616575A0000|34 48|brain structures
P00616575A0000|10 20|sensitivity
P00616575A0000|138 149|unit activity
P00616575A0000|101 103|EMF
P00617815A0215|12 25|L-R differences
P00618078A0367|1 8|decrease
P00618078A0367|14 29|lysozyme activity
P00618078A0367|54 64|improvement
P00618078A0367|79 88|meningitis
P00619305A0759|70 79|dimensions
P00619305A0759|18 23|groups
P00619305A0759|47 55|dimension
P00619782A0058|73 92|ultraviolet radiation
P00619782A0058|26 30|backs
P00619782A0058|4 7|tans
P00619782A0058|55 62|exposure
P00619782A0058|94 97|UV-A
P00619782A0058|33 42|volunteers
P00619948A0000|291 292|mg
P00619948A0000|57 62|tablet
P00619948A0000|173 185|blood pressure
P00619948A0000|4 10|effects
P00619948A0000|235 244|detachment
P00619948A0000|109 110|mg
P00619948A0000|163 171|heart rate
P00619948A0000|219 225|anxiety
P00619948A0000|19 26|subjects
P00619948A0000|281 288|diazepam
P00619948A0000|328 329|mg
P00619948A0000|227 233|tension
P00619948A0000|74 85|fluphenazine
P00619948A0000|314 324|propranolol
P00619948A0000|200 205|scales
P00619948A0000|145 147|CNV
P00619948A0000|135 143|variation
P00619948A0000|89 90|mg
P00619948A0000|40 43|dose
P00619948A0000|248 257|depression
P00619948A0000|94 106|nortriptyline
P00619948A0000|209 217|alertness
P00619948A0000|299 300|mg
P00619948A0000|150 161|reaction time
P00619948A0000|46 52|Motival
P00619948A0000|305 311|placebo
P00621626T0000|0 12|Stress effects
P00621626T0000|42 49|subjects
P00621626T0000|15 36|affiliation preferences
P00621626T0000|82 96|behavior pattern
P00621626T0000|63 66|type
P00622556A0111|16 23|collagen
P00622556A0111|30 35|tissue
P00622556A0111|64 69|tendon
P00623361A0221|28 39|contribution
P00623361A0221|0 6|Smoking
P00623361A0221|51 61|dysfunction
P00626014T0001|3 11|malignity
P00626014T0001|20 26|lentigo
P00627039T0000|0 10|Elimination
P00627039T0000|25 63|Louisiana paper manufacturing plant workers
P00627039T0000|13 22|bagassosis
P00627129A0944|174 191|beta-adrenoceptors
P00627129A0944|115 120|effect
P00627129A0944|30 35|others
P00627129A0944|45 52|subjects
P00627129A0944|5 13|responses
P00627129A0944|123 131|labetalol
P00627129A0944|65 74|conditions
P00627129A0944|155 162|blockade
P00627202T0000|0 8|Diuretics
P00627202T0000|49 51|use
P00627202T0000|23 34|pharmacology
P00628990A0000|33 37|units
P00628990A0000|157 160|loop
P00628990A0000|5 12|patients
P00628990A0000|170 181|ureterostomy
P00628990A0000|86 104|ureteroureterostomy
P00628990A0000|119 138|ureteroneocystostomy
P00628990A0000|63 76|reconstruction
P00630713T0000|0 9|Evaluation
P00630713T0000|15 39|Du Pont aca ammonia procedure
P00633909A0000|43 64|Internal-External Locus
P00633909A0000|135 142|patients
P00633909A0000|18 25|patients
P00633909A0000|98 106|treatment
P00633909A0000|171 177|control
P00633909A0000|67 78|Control Scale
P00633909A0000|35 40|Rotter
P00633909A0000|27 32|scores
P00635143T0001|0 5|Action
P00635143T0001|33 46|Cyprinus carpio
P00635143T0001|23 30|metaphos
P00635143T0001|8 19|strontium-90
P00635194A0093|0 12|Kodak XV-2 film
P00635194A0093|65 80|dose distribution
P00636526T0033|0 8|Diagnosis
P00636526T0033|24 32|diagnosis
P00637637T0000|57 68|hypertension
P00637637T0000|11 17|factors
P00637637T0000|27 45|plasma renin activity
P00639410T0000|43 61|lipid clearing agents
P00639410T0000|0 8|Cortisone
P00639410T0000|16 26|bone changes
P00639410T0000|33 40|response
P00640584A0250|46 54|stability
P00640584A0250|17 25|principle
P00641395A0441|150 165|extraction method
P00641395A0441|4 15|blood samples
P00641395A0441|30 47|hyperbilirubinemia
P00641395A0441|18 25|patients
P00641395A0441|126 131|levels
P00641395A0441|80 82|ZPP
P00641395A0441|67 77|measurement
P00641395A0441|89 99|fluorimeter
P00644314T0000|29 35|effects
P00644314T0000|46 60|anticoagulation
P00644314T0000|7 22|hypersensitivity
P00644314T0000|25 27|man
P00644539A0783|39 44|saline
P00644539A0783|66 66|%
P00644539A0783|53 56|FEV1
P00644539A0783|31 32|ml
P00644539A0783|115 123|reactions
P00644539A0783|18 27|inhalation
P00644539A0783|129 141|test solutions
P00644539A0783|106 112|subject
P00644539A0783|71 71|%
P00646023T0058|51 62|transmission
P00646023T0058|21 34|virus excretion
P00646023T0058|12 18|studies
P00646193T0000|0 6|Potency
P00646193T0000|20 23|dogs
P00646193T0000|9 17|enflurane
P00646193T0000|39 47|halothane
P00646193T0000|51 60|isoflurane
P00646193T0000|25 34|comparison
P00656008T0000|0 9|Prevention
P00656008T0000|41 59|superoxide dismutase
P00656008T0000|17 32|paraquat toxicity
P00656008T0000|35 38|rats
